B+
Bull case
20%
Probability
Target price
$1.15
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
PRFX
PRFCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.45
Analysis reference price unavailable
Analysis 2026-10-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+60.0
Score
AI commentary
Company filings establish development progress and a June funding cushion, but the packet has no recent trusted-news, social, options or analyst-revision coverage. The zero-valued sentiment fields indicate unavailable measurements, not neutral readings. Post-announcement price-reaction attribution is unavailable. The deterministic prior is neutral with low evidence quality (0.08) and high uncertainty (0.931), supporting a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-10-14
Open full AI memoEvidence flagged
Forward visibility is limited, so this memo should be read as a lower-conviction monitoring view rather than a catalyst-driven call.; no forward-looking company-specific catalyst is supported by primary-source evidence; peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-06-25eventPRF-110 expanded preclinical benchmark dataMedium impact
PRF reported comparable analgesic efficacy to ZYNRELEF in a porcine post-operative pain model, alongside slower absorption and enhanced local tissue retention. These issuer-reported findings support further study but do not establish efficacy in humans. [#PR-EARNINGS-2026-06-25] Company release
2026-09-03eventFirst-half results and funding positionMedium impact
The September 3 update reported approximately $11.6 million in cash and related balances at June 30, against a $2.8 million first-half loss attributable to shareholders. The stronger balance sheet supports development, but its improvement followed equity issuance. [#SEC-6K-2026-09-03] SEC exhibit
2026-12-31eventOcuRing-K Phase II enrollmentHigh impact
PRF said FDA clearance of the IND enabled a U.S. Phase II cataract-surgery trial and expected enrollment in the second half of 2026. Enrollment would mark execution progress, not proof of efficacy. [#SEC-6K-2026-09-03] SEC exhibit
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-14 • Updated nightlySource: Internal modelMethodology